Loading organizations...
§ Private Profile · Singapore, Central Region, Singapore
Precision gut microbiome company developing diagnostics, probiotics, and interventions for Asian consumers, operating SEA's only microbiome bank.
Based in Singapore, AMILI is a pioneering precision medicine company developing gut microbiome diagnostics, sequencing services, and personalized probiotic formulations specifically tailored for Asian consumer populations. The organization operates Southeast Asia’s only fecal microbiota transplant bank and maintains an extensive multi-ethnic Asian microbiome database to support clinical research, food manufacturers, and biopharma partnerships. Operating through commercial business-to-business channels and its proprietary direct-to-consumer brand BIO & ME, the enterprise has successfully conducted over twenty research studies valued at more than $40 million. To finance its ongoing regional expansion across Southeast Asia and Hong Kong, AMILI secured $10.5 million in a 2022 Series A funding round backed by institutional investors including Vulcan Capital, East Ventures, and TVM Capital Healthcare. The innovative biotechnology company was officially founded in 2019 by Jeremy Lim, David Ong, and Jonathan Lee.
AMILI has raised $10.5M across 1 funding round.
AMILI has raised $10.5M in total across 1 funding round.
AMILI has raised $10.5M across 1 funding round. Most recently, it raised $10.5M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 16, 2022 | $10.5M Series A | Tommy TEO | Blue7, Capital Code, Emtek Group, Enterprise Singapore, Pruksa Group, Pureland Global Venture, Seeds Capital, TVM Capital Healthcare | Announced |
AMILI has raised $10.5M in total across 1 funding round.
AMILI's investors include Tommy Teo, Blue7, Capital Code, Emtek Group, Enterprise Singapore, Pruksa Group, Pureland Global Venture, SEEDS Capital, TVM Capital Healthcare.